Susquehanna International Group, LLP Prothena Corp Public LTD CO Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$16.73 - $24.79 $393,155 - $582,565	23,500 Added 74.13%	55,200 $923,000
Q2 2024 Aug 15, 2024	SELL	$19.54 - $26.15 $1.38 Million - $1.84 Million	-70,500 Reduced 68.98%	31,700 $654,000
Q1 2024 May 07, 2024	SELL	$24.75 - $40.66 $4.77 Million - $7.84 Million	-192,900 Reduced 65.37%	102,200 $2.53 Million
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $8.97 Million - $14.5 Million	277,600 Added 1586.29%	295,100 $10.7 Million
Q3 2023 Nov 14, 2023	SELL	$47.3 - $70.6 $1.04 Million - $1.55 Million	-22,000 Reduced 55.7%	17,500 $844,000
Q2 2023 Aug 11, 2023	BUY	$48.26 - $78.59 $1.14 Million - $1.86 Million	23,700 Added 150.0%	39,500 $2.7 Million
Q1 2023 May 16, 2023	SELL	$46.97 - $58.27 $3.11 Million - $3.86 Million	-66,300 Reduced 80.76%	15,800 $765,000
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $1.38 Million - $1.72 Million	-26,500 Reduced 24.4%	82,100 $4.95 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $1.96 Million - $4.72 Million	77,800 Added 252.6%	108,600 $6.58 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $698M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.